Electrophysiology of Hypokalemia and Hyperkalemia.
James N Weiss, Zhilin Qu, Kalyanam Shivkumar
https://pubmed.ncbi.nlm.nih.gov/28314851/Actively Recruiting
Led by Saglik Bilimleri Universitesi · Updated on 2024-10-10
40
Participants Needed
1
Research Sites
N/A
Total Duration
This research investigates patients with chronic kidney disease CKD who have an estimated glomerular filtration rate eGFR below 60 mLmin1.73 m and present to the emergency department with isolated high potassium levels hyperkalemia. The study aims to examine electrocardiogram ECG and echocardiography ECHO findings in these patients and their association with early and late mortality. Researchers will compare these findings to existing literature to better understand the cardiac effects of hyperkalemia in CKD patients. Participants will form a single group of patients diagnosed with hyperkalemia. Blood samples will be taken to measure potassium levels, followed by ECG and ECHO tests before and after treatment. The ECHO is performed by an experienced physician who is not involved in treatment decisions. The study does not interfere with any medical interventions, which remain under the care of the responsible physician. Throughout the study, data from ECG, ECHO, and laboratory tests will be collected and analyzed. Mortality will be tracked at 24 hours, 7 days, and 30 days after enrollment, excluding other causes of death. The main outcome is to observe changes in echocardiographic findings over 30 days. This study also explores the potential link between cardiac imaging changes due to hyperkalemia and patient survival, offering insight into the usefulness of combined ECG and ECHO monitoring.
CONDITIONS
Chronic Kidney Disease, Hyperkalemia and Echocardiographic Changes
G
Gulsen AKCAY, Ass. Prof.
E
Emre CAKAR, Resident
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Saglik Bilimleri Universitesi
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 30 days
Participants undergo ECG and echocardiography (ECHO) tests along with blood sampling to measure potassium levels. These assessments are performed before and after treatment to record cardiac function and changes.
1 visit at enrollment and additional visits as needed for post-treatment assessments
Duration - 30 days
Participants are monitored for mortality outcomes at 24 hours, 7 days, and 30 days after enrollment to evaluate the relationship between ECG and ECHO findings and mortality.
Follow-up contacts or assessments at 24 hours, 7 days, and 30 days
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
James N Weiss, Zhilin Qu, Kalyanam Shivkumar
https://pubmed.ncbi.nlm.nih.gov/28314851/Andrew Piner, Ryan Spangler
https://pubmed.ncbi.nlm.nih.gov/37758419/Michael J Kim, Christina Valerio, Glynnis K Knobloch
https://pubmed.ncbi.nlm.nih.gov/36689973/Saglik Bilimleri Universitesi
Lead Sponsor